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Summary Sera of 85 patients with benign soft tissue lesions or sarcomas of soft tissues were investigated for a
collagen metabolite, the aminoterminal propeptide of type III procollagen (PIIINP). Patients were divided into
three groups: benign soft tissue lesions (n = 39), localised (n = 29) and metastatic (n = 18) soft tissue sarcomas
(STS). Values of PIIINP above the reference range were found in 15%, 28% and 50% of the respective
groups. The difference in the concentration of PIIINP was statistically significant between the benign lesions
and the localised sarcomas; P = 0.05, and between the benign lesions and the metastatic sarcomas; P<0.001.
In localised sarcomas there was a correlation between PIIINP and bone-involvement (r = 0.61, P = 0.002) and
in metastatic disease between PIIINP and liver metastases (r=0.77, P<0.001). In localised sarcomas the
overall survival for patients with a value of PIIINP above the reference range was significantly poorer
(P = 0.03) than for patients with values within the reference range, even after stratification for the histological
malignancy grade of the tumours (P = 0.04).
In malignant disease connective tissue metabolism may be
involved in different mechanisms. The tumour may degrade
matrix components in association with invasion, and there
may be an increased production of matrix components by the
host and/or by the tumour (Liotta et al., 1983). Several
methods have been developed that can be used to detect
increased extracellular matrix metabolism in the body by a
simple study of blood samples (Risteli & Risteli, 1989). The
assay for the aminoterminal propeptide of type III procolla-
gen (PIIINP) has been commercially available and thus most
often used. High levels of PIIINP have been found in
patients with various cancers, particularly primary and secon-
dary liver cancer (Bolarin et al., 1982), but also in bone
sarcomas (Elomaa et al., 1989a; Elomaa et al., 1989b).
Type III collagen is found mainly in tissues such as skin,
arteries and the uterus, muscle, liver and lung, bone marrow
and periosteum (Prockop et al., 1979). During synthesis of
interstitial fibre-forming collagens (types I, II, III and V),
procollagens with additional propeptide extensions at both
ends of the molecule are formed first. These propeptides are
cleaved off before the formation of collagen fibrils. The
aminoterminal propeptides of type III procollagen are, how-
ever, not constantly cleaved off. Such type III collagen mole-
cules which have retained the aminoterminal propeptides,
called type III pN collagen, are usually found on the surface
of collagen fibres (Fleischmajer et al., 1985).
The propeptide is mainly eliminated by the liver endo-
thelial cell (Smedsr0d, 1988). Because its half-life in serum is
only a few minutes, its presence indicates active collagen
synthesis and turnover (Smedsr0d, 1988). Quantification of
the PIIINP antigen has been achieved by specific radio-
immunoassays (Risteli et al., 1988a). The antigen in serum is,
however, heterogeneous, due to forms larger and smaller
than the authentic propeptide (Niemeli et al., 1982). The
interference caused by the small degradation products of the
propeptide has been successfully eliminated in the assay mod-
ification used in this study (Risteli et al., 1988a). It is not
known, however, whether the large PIIINP antigens are
aggregates containing the authentic propeptide, or degrada-
tion products of tissue type III pN collagen (Niemela et al.,
1982).
The aim of the present study was to elaborate on whether
there are differences in the serum concentration of PIIINP in
patients with benign soft tissue lesions and soft tissue sar-
comas (STS) of different stages, and to study whether the
propeptide level could be correlated with any clinical findings
or used as a prognostic marker.
Materials and methods
Patients
The material studied consists of all the patients attending
Helsinki University Central Hospital for a verified or suspect-
ed non-osseous sarcoma between May 1988 and October
1990. Samples from patients with benign lesions and sar-
comas without evidence of metastases at time of sampling
were taken preoperatively and from patients with metastatic
sarcomas before surgery was performed or chemotherapy
started. Excluded were patients under the age of 16 years,
patients operated on within 1 year before sampling (with the
exception of patients having minor incision biopsies), and
patients who had received chemotherapy within 1 year before
sampling.
Eighty-six samples from 85 patients met our inclusion
criteria. These were divided into three groups; patients with
benign soft tissue lesions of the trunk and the extremities
(n = 39), patients with sarcomas without evidence of metas-
tases at the time of sampling (n = 29) and patients with
metastases present at the time of sampling (n = 18). Seven
localised and 40 metastatic sarcomas were excluded because
of recent surgery or chemotherapy. In the analysis local
recurrences were regarded as new primaries. In each group,
however, each patient was included only once. All tumours
were histologically confirmed with the exception of a few
benign lesions whose benign nature were judged on clinical
or radiological grounds. Tumours were histologically graded
using a four-graded scale (Markhede et al., 1982). In the
analysis high grade tumours were those of malignancy grade
three and four, and low grade tumours those of grade one
and two.
Fourteen of the benign lesions were lipomas, five neurile-
momas, three elastofibromas and two desmoid tumours,
hemangiomas and myositis ossificans each. Eleven were mis-
cellaneous soft tissue lesions or tumours, one of each.
The histological subtypes of the sarcomas are presented in
Table I. Twenty-six of the localised sarcomas were extremity
tumours, two were in the head and neck region (one super-
ficial and one intraoral) and one was retroperitoneal. Five
were locally recurrent tumours. Localised sarcomas of the
trunk and the extremities were further classified as for
tumour location and depth, compartmental status, presence
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Table I Histological subtypes of sarcomas at study by stage of
disease
Number ofpatients
Localised Metastatic
Histologic type sarcomas sarcomas
Malignant fibrous histiocytoma 6 3
Liposarcoma 6 3
Leiomyosarcoma 4 4
Malignant schwannoma 4 1
Fibrosarcoma 2
Undifferentiated sarcoma 2 3
Other specified sarcoma 5 4
of bone-, vessel- or nerve-involvement and size at the time of
serum sampling. One retroperitoneal and one intraoral
tumour were classified as deep. The preoperative size of the
tumour was determined as the maximal diameter of the
tumour either on clinical or on radiological grounds or from
the operative specimen. Fifteen patients were treated by
surgery alone, 11 patients received postoperative radio-
therapy, one patient with an inoperable intraoral tumour was
prescribed radical radiotherapy and two patients were
observed, one refused therapy and the other had a locally
recurrent intraabdominal tumour of low malignancy grade
which previously had not responded to therapy. The patients
were regularly followed-up and the follow-up data were
obtained from the hospital records and population registries.
Of the patients with metastatic disease, seven had a simul-
taneous primary or locally recurrent tumour. The primary
tumour was in seven cases an extremity tumour, in one case
a superficial tumour of the neck, in five cases a retro-
peritoneal tumour and in five cases the location was either
bowel, uterus, lung, brain or splenic hilus. Eleven patients
had lung metastases, five had bone metastases and four
patients had liver metastases. Seven patients had more than
two metastatic sites (excluding two cases with lung metas-
tases with pleural spread).
Other diseases which might affect the connective tissue
metabolism were recorded from the hospital records. Two
patients had severe osteoarthritis of the knee joint, and six
patients had elevated liver enzymes (patients with liver metas-
tases excluded).
Radioimmunoassays
The concentration of PIIINP was analysed with an equilibrium
type of radioimmunoassay (Risteli et al., 1988a) based on a
human antigen (Farmos Diagnostica, SF-90460 Oulunsalo,
Finland), using 200 tl aliquots of serum. The assay detects
the authentic propeptide and another, somewhat larger relat-
ed antigen, but it is not sensitive to the smaller degradation
products of the propeptide. In this assay modification the
standards and serum samples give parallel inhibition curves.
The intra- and interassays coefficients of variation of the
method are about 5% (Risteli et al., 1988a).
Serum was stored at -20°C until analysed. The reference
range of PIIINP among adult Finnish blood donors is 1.7-
4.2 jig I' (mean ± 2 s.d.) (Risteli et al., 1988a).
Statistical analysis
Confidence intervals (CI) for proportions were calculated for
a binomial distribution. Bivariate correlations were tested
by the unpaired, two-tailed t-test using the logarithm of
the serum concentration value. Correlations were further
analysed with a step-wise linear regression model and differ-
ences in survival with the test of Mantel-Cox.
Results
The mean and 95% confidence interval, and the distribution
of PIIINP in the patients with benign lesion, localised and
metastatic STS are presented in Table II and Figure 1.
Table II Mean and 95% confidence interval of PIIINP (jigI-') in
benign soft tissue lesions, localised soft tissue sarcomas and metastatic
soft tissue sarcomas
Number
Tumour group ofpatients Mean CI
I Benign lesions 39 3.05 2.66-3.43
II Localised sarcomas 29 3.83 3.11-4.54
III Metastatic sarcomas 18 5.49 3.45-7.52
log (S-PIIINP): I vs II; P = 0.05, II vs III; P = 0.07, I vs III;
P = 0.0004, (t-test, unpaired, two-tailed).
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Figure 1 PIIINP in patients with benign lesions, localised and
metastatic soft tissue sarcomas. Box plot with the 10, 25, 50, 75
and 90th percentiles. The individual values are represented as
black dots. Note logarithmic scale.
Benign lesions
Six of 39 patients with benign lesions had elevated PIIINP
levels (15%, CI 7-28%). These included a case of
fibromatosis and a case of nodular fascitis in which the
apposed bone was affected, although no infiltration into the
bone was detected. In another patient the lesion was found to
be inflammatory and granulomatous. One further patient
with an intramuscular lipoma had been treated for breast
cancer one and a half years previously; she has had no signs
of recurrent breast cancer during a follow-up time of 1 year.
Another patient had a tumour that turned out to be a
chronic synovitis of the semimembranotic bursa containing a
large cartilage formation. In the last patient PIIINP was only
marginally elevated (4.3 jg I`). In this group one patient had
osteoarthritis and two had elevated liver function tests, none
of these had an elevated PIIINP.
Localised sarcomas
Eight out of 29 patients with localised sarcomas had values
of PIIINP above the reference range (28%, CI 15-44%). In
further evaluating the localised sarcomas with pairwise com-
parison and stepwise linear regression using the following
variables; location (trunk vs extremity), depth (superficial vs
deep), compartment (intra vs extracompartmental), bone-
involvement (yes vs no), vessel-involvement (yes vs no),
nerve-involvement (yes vs no), size (< 5 cm vs > 5 cm) and
histopathological grade (low vs high), the only variable that
turned out to be significant was bone-involvement (r = 0.61,
P = 0.002). Three patients were included in this group; in one
there was radiologic evidence of infiltration of the bony
pelvis, in another there were changes in the femur which were
interpreted as caused by pressure from the tumour and in a
further case the scapula was totally embedded by the tumour.
The results of the pairwise comparisons are shown in Table
III. Elevated levels of PIIINP were not associated with any
specific histologic subtype. Nine of the patients in this group
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Table III Correlation ofdifferent clinical and histological parameters
with PIIINP in localised soft tissue sarcomas
PIIINP
Variable Groups Count r P
Location Trunk vs extremity 5/24 -0.04 0.70
Depth Superficial vs deep 5/24 -0.19 0.51
Compartment Intra- vs extra- 6/23 0.20 0.27
compartmental
Bone-involvement No vs Yes 26/3 0.61 0.002
Vessel-involvement No vs Yes 28/1 0.22 0.21
Nerve-involvement No vs Yes 26/3 -0.10 0.72
Size 5cm vs >5cm 7/22 0.07 1.0
Grade Low vs high 8/21 0.13 0.78
r = correlation coefficient, P = P-value.
have had metastases during the follow-up; seven patients
have died. All patients who died had active tumours. Median
follow-up was 1.3 years. Patients having an initial value of
PIIINP higher than the upper reference limit had a
significantly (P = 0.03) poorer overall survival than those
with a PIIINP within the reference range (Figure 2). Grade,
size and bone-involvement were also tested for the overall
survival (P = 0.05, 0.17 and 0.04). No patient with a low
grade tumour died. After stratification for grade there was
still a significant correlation between PIIINP and overall
survival (P = 0.04). After exclusion of those three patients
with bone-involvement the significance of PIIINP on survival
was lost (P = 0.13), there was, however, still a considerably
difference in the survival (2-year survival for patients with
PIIINP above the reference range was 39% and within the
reference range 82% respectively). The effect of PIIINP on
metastases free survival was less pronounced (P = 0.12). In
this group one patient had osteoarthritis and two had
elevated liver function tests, two of these had an elevated
PIIINP level.
Metastatic sarcomas
PIIINP was above the reference range in nine of 18 patients
(50%, CI 31-71%). In seven patients with metastatic disease
the only site of metastases was the lungs including two
patients with additional pleural spread (both had PIIINP
values within the reference range). In three patients with lung
metastases PIIINP was above 4.2 jg 1'. High values (>7.0
.tg 1-1) were found in three patients with extensive metastatic
lesions in the liver. Three out of four patients with liver
metastases had markedly elevated liver function tests. Two
patients had elevated liver function tests without liver metas-
tases, one of these had an elevated PIIINP level. When the
value of PIIINP was tested for each metastatic site there was
a significant positive linear correlation between the presence
of liver metastases (r = 0.77, P<0.001) and a value of
Time (years)
Figure 2 Overall survival for patients with a initially elevated
value of PIIINP (>4.2ftgl-') (*) and patients with PIIINP
within the reference range (<4.2p1g -') (O).
PIIINP above the reference range. No other metastatic site
(lung, bone, multiple) showed any clear correlation to the
PIIINP level after inclusion of liver metastases in a stepwise
regression analysis.
Discussion
In this prospective cross-sectional study we have examined
the serum level of PIIINP in patients with benign soft tissue
lesions and soft tissue sarcomas and its relationship to clin-
ical and histopathological parameters of the tumours at the
time of serum sampling.
Elevated levels of PIIINP have previously been reported in
cross-sectional studies on various cancers, especially liver
cancer as well as in various gynaecological cancers and in
mammary cancer with skeletal metastases (Bolarin et al.,
1982; Risteli et al., 1988c; Toma's et al., 1990b; Blomqvist et
al., 1987). In follow-up studies on ovarian cancer the level of
PIIINP follows the clinical behaviour and the level of CA-
125 (Tomfas et al., 1990a). In previous studies by us on
sarcomas of bone, the antigen appears to be a good indicator
of the clinical behaviour of the disease (Elomaa et al., 1989a;
Elomaa et al., 1989b).
Several conditions other than malignancies that elevate the
level of PIIINP have been identified, including normal
growth and pregnancy, as well as rheumatoid arthritis and
osteoarthritis (Risteli et al., 1988a; Risteli et al., 1987; H0rs-
lev-Petersen et al., 1988). During normal and pathological
wound healing after moderate to major surgery there is a
marked elevation of the level of PIIINP with a maximum
within 30 days postoperatively and a slow decrease. Slightly
higher levels than the preoperative can be detected up to half
a year postoperatively (Haukipuro et al., 1990). High levels
are also detected in various liver diseases, as during long-
term low dose chemotherapy with methotrexate for psoriasis
(Risteli et al., 1988b).
In this first cross-sectional report on PIIINP in benign soft
tissue lesions and soft tissue sarcomas we have, on the basis
of previous literature, excluded possible confounding effects
of surgery or chemotherapy on the level of PIIINP in an
attempt to discriminate the unmasked effect of the tumour on
the collagen metabolism. No data on the effect of radio-
therapy on the serum level of PIIINP are currently available,
however, only one of our patients with a metastatic sarcoma
had recently received radiotherapy. In eight patients condi-
tions known to affect the collagen metabolism were present
(i.e. rheumatoid arthritis, osteoarthritis and liver disease).
However, an elevated PIIINP was detected in only three of
these patients.
The present study indicates that there is a relationship
between PIIINP and the stage of the disease in sarcomas of
soft tissues. If it is evaluated as a tumour marker there are
however false positive values among benign tumours as well
as a large proportion of false negative values among patients
with localised and metastatic sarcomas. PIIINP was espec-
ially sensitive in detecting bone-involvement in local disease.
There was, however, only one case of evident infiltration of
the tumour in the bone. Moreover two patients with benign
tumours being in close relation to the bone had pathological
values of PIIINP. This finding may be explained by a perios-
tal reaction rather than a reaction of the mineralised bone or
bone marrow. The source of an elevated PIIINP in the four
additional patients with benign lesions is not clear, however,
it may have been associated with inflammatory conditions in
two patients. The highest value was detected in a woman
previously treated for breast cancer, but at the time of the
sampling she had no apparent reason for an increased colla-
gen metabolism.
In this series there appears to be a correlation between the
prognosis of localised sarcomas and the preoperative value of
PIIINP. This finding is encouraging and needs further confir-
mation as well as clarification of the mechanism. Although
partly explained by the association with bone-involvement
this correlation appears to be independent from most other
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known prognostic factors.
In metasatic disease the highest values were found in cases
of liver metastases. The circulating propeptides are cleared
mainly by the liver (Smedsr0d, 1988). High serum values may
thus in part be explained by decreased secretion of PIIINP
by the liver. There were however, also pathological values in
three of seven patients with metastases confined only to the
thoracic cavity (lung and pleura), which in a general popula-
tion of patients with STS is the predominant metastatic site.
Due to our inclusion criteria, primary metastatic tumours
may be over-represented in this material.
The source of PIIINP is unclear. Due to the incomplete
removal of the aminoterminal propeptide and the hetero-
genity of the antigen the assay for PIIINP may measure
either synthesis or to some extent also degradation of type III
collagen. One can speculate that the lack of correlation with
tumour size and histologic subtype, the correlation with
bone-involvement and the suggested prognostic value of
PIIINP all indicate that the rise in collagen III metabolism
appears outside the tumour, presumably by increased degra-
dation. In addition, in case of liver metastases, the level of
PIIINP may increase due to impaired excretion.
Tumour markers would be especially valuable in assessing
prognosis, for early diagnosis of recurrence and in early
response evaluation during treatment of advanced STS with
chemotherapy. We have found elevated values of S- PIIINP
in a minority of cases of localised sarcomas and in a con-
siderably number of cases of metastatic sarcomas. These
preliminary findings also revealed a prognostic value of pre-
operative PIIINP in localised sarcomas. The limitations for
the use of PIIINP as a tumour marker are, however, con-
siderable due to the effects of recent surgery and possibly
chemotherapy. In this study we excluded these patients. The
value of PIIINP may not either be diagnostically helpful in
the individual cases, due to considerable overlap between the
groups studied. The value of PIIINP during the follow-up of
soft tissue sarcomas as well as during chemotherapy and
radiotherapy of sarcomas are being studied.
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